Pharmacological closure of the patent ductus arteriosus: when treatment still makes sense
- PMID: 31591487
- PMCID: PMC7055580
- DOI: 10.1038/s41372-019-0518-3
Pharmacological closure of the patent ductus arteriosus: when treatment still makes sense
Conflict of interest statement
Figures
References
-
- Schmidt B, Davis P, Moddemann D, Ohlsson A, Roberts RS, Saigal S, et al. Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants. N Engl J Med. 2001; 344:1966–72. - PubMed
-
- Bixler GM, Powers GC, Clark RH, Walker MW, Tolia VN. Changes in the diagnosis and management of patent ductus arteriosus from 2006 to 2015 in United States neonatal intensive care units. J Pediatr. 2017;189:105–12. - PubMed
-
- Hagadorn JI, Brownell EA, Trzaski JM, Johnson KR, Lainwala S, Campbell BT, et al. Trends and variation in management and outcomes of very low-birth-weight infants with patent ductus arteriosus. Pediatr Res. 2016;80:785–92. - PubMed
-
- Lokku A, Mirea L, Lee SK, Shah PS, Canadian Neonatal N. Trends and outcomes of patent ductus arteriosus treatment in very preterm infants in Canada. Am J Perinatol. 2017;34:441–50. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
